In a double-blind, placebo-controlled clinical trial (power of 80% to detect a 30% reduction in morphine consumption, P<0.05) we have determined that intraoperative intravenous administration of tenoxicam 40 mg during laparoscopic cholecystectomy, when compared with placebo, was associated with a significant reduction in consumption of morphine at 6 hours and 12 hours (P<0.05) but not at 24 hours, when assessed by patient-controlled analgesia. Furthermore there was a significantly greater requirement for "rescue" analgesia with intramuscular morphine in the placebo group during the period of the study. There was no difference between the groups in pain scores, either at rest or on movement, nor in the incidence of nausea and vomiting. No patient in either group suffered a respiratory rate less than 8/min or oversedation at any time, and there were no other adverse effects.
Non-steroidal anti-inflammatory drugs (NSAIDS) are used extensively for postoperative analgesia 1,2 . Tenoxicam, a thienothiazide derivative of the oxicam class of NSAIDS, is a relatively new analgesic which compares favourably with others in its class when used in its oral preparation for the longterm treatment of rheumatological conditions 3 . Perioperatively, tenoxicam has already shown a morphine-sparing effect in major surgery (thoracotomy) 4, 5 , and to be superior to diclofenac sodium in maxillofacial surgery when continued as its oral preparation for seven days postoperatively 6 .
In addition to the oral preparation, tenoxicam has been introduced in Europe, although not as yet in Australia, as an intravenous injectate (Roche Products Ltd). Intravenous administration is preferable both in the immediate postoperative period, in order to avoid any delay in absorption from either intramuscular or enteral routes, and before surgery as the most certain mode of drug delivery. The drug has a long plasma half-life concentration (60-70 hours). The manufacturers (Roche Products Ltd) recom-mend a once daily dosage of 20 mg 7 . As tenoxicam has such a long half-life it may be expected not to reach effective plasma concentration until after several doses. This has been suggested by Merry et al who performed a double-blind, placebo-controlled trial using 20 mg tenoxicam in patients following thoracotomy . They demonstrated an opioid-sparing effect, but suggested that a larger single dose of tenoxicam may be more efficacious 4 . Windsor et al failed to demonstrate improved analgesia after diagnostic laparoscopy when comparing intravenous tenoxicam 20 mg plus fentanyl with fentanyl alone. They also suggest a 40 mg loading dose might be more appropriate 8 .
The increasing utilization of laparoscopic techniques is resulting in less overall pain and a decreased hospital stay for many patients. Standard opioid analgesia may result in oversedation and nausea and vomiting in otherwise mobile patients.
We chose to assess the morphine-sparing effect of a single intravenous dose of 40 mg tenoxicam in patients following laparoscopic cholecystectomy, using patient-controlled analgesia (PCA) in a prospective, placebo-controlled, double-blind study.
METHODS
Ethics committee approval was obtained. We predicted the power of the study using a one-tailed t-test, assuming tenoxicam to reduce morphine requirements by 15 mg compared to a control requirement of 48 mg/24 h (30%). With 20 patients in each group this study had an 80% power to detect such a difference at the P<0.05 level of significance.
After giving written informed consent a total of 40 patients, all undergoing laparoscopic cholecystectomy, were recruited. At this time the anaesthetist explained the postoperative assessments to the patient. These utilized a 100 mm visual analog scale for subjective assessment of pain and a three-point categorical score for pain on movement. The patients were randomly allocated to either tenoxicam or placebo receiving groups. Criteria for exclusion were: age<18 or >70 years; known hypersensitivity to NSAIDs; any possibility of pregnancy; administration of an NSAID or opioid during the 24 hours preceding surgery; concurrent treatment with diuretics or angiotensin-converting enzyme inhibitors; a previous history of asthma, peptic ulceration, gastrointestinal bleeding or bleeding disorder; presence of renal impairment (creatinine >130 µmol/l); hepatic, cardiac or haemopoietic disease or inability to operate a PCA device.
All patients were premedicated with oral temazepam 20 to 30 mg one to two hours preoperatively. All received a standardized anaesthetic. Anaesthesia was induced using propofol 2 to 3 mg/kg and vecuronium 0.1 mg/kg for muscle relaxation. Anaesthesia was maintained with 30% oxygen in nitrous oxide and enflurane or isoflurane. All were given morphine 0.1 mg/kg intravenously. No local or regional techniques were used. On skin closure either 40mg intravenous tenoxicam or placebo as previously randomized was administered by an anaesthetist not involved in the study follow-up. After transfer to the recovery area a Graseby 3300 PCA pump was set up. A loading dose of 0.05 mg/kg morphine was given intravenously, thus bringing total perioperative morphine administered to 0.15 mg/kg, then the pump set to administer a 1 mg bolus with a five-minute lock-out and no background infusion. All patients were also prescribed rescue analgesia of 5 mg IM morphine in the event of pain scores above 50 for at least 30 minutes, despite appropriate use of the PCA.
In addition to hourly PCA pump delivery checks and respiration counts by the nursing staff, all patients were assessed at 2, 4, 6, 12 and 24 hours by an independent observer unaware of the group to which the patient had been allocated. The assessments were made using an unmarked 100 mm visual analog scale (VAS) from no pain to worst pain ever experienced; a categorical score for pain on movement (mild, moderate or severe on taking a deep breath); sedation level (awake; asleep-easily roused; asleep-difficult to rouse or unrousable); respiratory rate, heart rate and blood pressure; nausea score (none, moderate or severe); presence or absence of vomiting or anti-emetic administration since previous assessment. Any other adverse effects were recorded whether or not they were thought to be related to the study.
Statistics were analysed by non-parametric (Wilcoxon Rank Sum, or chi-square with Yates correction as appropriate) or parametric (t-test, ANOVA or repeated measures ANOVA) methods as indicated. A significance level of P<0.05 was employed.
RESULTS
Three of the 40 patients in the study were withdrawn (one from the placebo group and two from the tenoxicam group) due to requiring open surgery for cholecystectomy after failure to perform the procedure laparoscopically.
The study patients were predominantly female (M:F tenoxicam 4:15; M:F placebo 3:15) with no significant differences in the proportions between the two groups (Table 1 ).
There was no significant age difference between the tenoxicam group (mean 51.6 years; SD 13.5) and the placebo group (mean 50.0 years; SD 14.5). However the tenoxicam group were significantly heavier (mean 78.7 kg; SD 9.7) compared with the placebo group (mean 67.4 kgs; SD 13.8) (ANOVA P=0.011).
Morphine consumption, assessed by PCA (excluding the loading dose), is shown in Table 2 . At all times morphine use was greater for the placebo group. This reached statistical significance at 6 hours, when morphine consumption was reduced by 42%, and at 12 hours when it was reduced by 41%(both P<0.05, one-tailed t-test). Although morphine use was reduced by 35% at 24 hours, this was not statistically significant. Furthermore, there was no significant difference in consumption across the time periods 6 to 12 and 12 to 24 hrs. Thus the main difference in PCA morphine consumption occurred in the first 6 hours postoperatively.
No patient in the tenoxicam group required the prescribed "rescue" analgesia of 5 mg IM morphine. However, five patients in the placebo group did so, on When the 24 hour consumption of morphine by PCA in each of the two groups is added to the respective consumption of rescue analgesic, there was a significant difference in the total morphine use over 24 hours. The tenoxicam group required a mean of 17.4 mg (SD 15.5), compared with the placebo group (mean 30.9 mg, SD 22.6) (one-tailed t-test, P<0.025). This represents a 44% reduction in mean total morphine consumption over the 24 hour period.
When mean total 24 hour morphine consumption is expressed relative to body weight, the difference is even more striking: 0.46 mg/kg in the placebo group, compared with 0.22 mg/kg in the tenoxicam group.
Although the pain scores at rest (Figure 1 ) assessed by 100 mm unmarked VAS were always lower in the tenoxicam group, this did not reach statistical significance (repeated measures ANOVA). There were no important differences between the two groups for pain on movement at any time. There were no significant differences in nausea and vomiting scores between the tenoxicam and placebo groups (moderate to severe 5 vs 7) nor anti-emetic requirement (7 vs 11) (Wilcoxon Rank Sum). The tenoxicam patients vomited on a total of 12 occasions compared with 15 occasions in the placebo group (Table 3) .
No patient in either group recorded a respiratory rate of <8 or sedation level 2 to 3 (i.e. moderate to severe) at any time. No other adverse event was recorded: specifically, no patient's recovery was complicated by renal dysfunction(urea >8 mmol/l and/or creatinine >130 µmol/l) or a bleeding problem.
DISCUSSION
We chose intravenous administration of tenoxicam in preference to either intramuscular or enteral administration as the most certain mode of drug delivery as it avoids any delay in absorption from either intramuscular or enteral routes in the perioperative period. Also, when concurrently prescribing oral premedication, this method of administration reduces the number of tablets required to be ingested by the patient. The adverse effects attributed to NSAID usage include impaired platelet function and decreased renal function. These side-effects would have been of particular concern in the event of significant intraoperative bleeding. The preoperative administration of tenoxicam might, in addition, increase the severity of any intraoperative bleeding. (Moreover, preinduction administration of a NSAID is unlikely to confer any additional pre-emptive analgesic benefit 9 .) We thus administered the tenoxicam on skin closure and after uneventful surgery.
As the numbers of surgical cases performed laparoscopically increases there are an increasing number of patients being mobilized and discharged earlier from hospital. Analgesia thus requires to be effective without oversedating the patient. Although patients do not suffer such severe wound pain following laparoscopic cholecystectomy as compared with the traditional Kocher's incision, they do suffer shoulder-tip pain referred from diaphragmatic irritation and generalized abdominal discomfort from residual gas and possible spilled blood and/or bile.
Our results demonstrate a reduction in morphine consumption in the tenoxicam group at all times, with no increase in pain scores either at rest or on movement. This reduction in morphine consumption only reached significance at 6 hours (42%) and 12 hours (41%), and indeed the main difference occurred in the first 6 hours. The fact that the tenoxicam group was significantly heavier should be born in mind, but it may be that the effect of tenoxicam for postoperative analgesia is much shorter lived than would be expected from its long plasma half-life and from clinical experience in rheumatological conditions. Merry et al 4 also found its beneficial effect to be confined to the first 12 hours postoperatively, although they used a dose of only 20 mg, and suggested that a larger dose might have a longer duration of effect.
Our results suggest that this is not the case.
When the amount of morphine given IM as "rescue" analgesia is added to the 24 hour PCA consumption there was a highly significant reduction in total morphine used, amounting to 44% of the total used by the placebo group. This reduction is even more striking when related to body weight. A total of 0.46 mg/kg was used by the placebo group compared with only 0.22 mg/kg by the tenoxicam group.
We must consider why the patients requesting "rescue", intramuscular analgesia did not simply use their PCA more frequently. It may be that their pain was too severe to be overcome by the 1 mg morphine PCA boluses or, perhaps, they had been previously conditioned to expect an intramuscular injection for pain 10 . Recent work has shown that a variety of factors, other than simply degree of pain, influence the self-administration of opioids by PCA 11 . Whatever the explanation, it was only patients in the placebo group who required "rescue" analgesia.
Previous studies have failed to demonstrate any benefit from NSAID use when combined with an opioid as analgesia for laparoscopic sterilization 12, 13 . Hence it is notable that tenoxicam produced such a reduction in morphine consumption following more painful surgery. It is obvious that patients after laparoscopic cholecystectomy will have higher analgesic requirements than after laparoscopic sterilization due to the more traumatic surgery and the longer gas insufflation time.
Although there was a decrease in VAS at rest in the tenoxicam group at all times, this did not reach statistical significance. We chose to use a categorical scale for pain on movement in order to minimize the number of VAS scores required. In our experience these are unpopular with patients particularly when a large number of assessments must be made. Again no significant difference was detected. Hence the use of intravenous tenoxicam appears not to produce any clinically useful synergistic effect on pain scores.
Although, overall, the patients receiving tenoxicam did use significantly less morphine than the placebo group, there was little difference in the incidence of nausea, vomiting or sedation. This may suggest that other factors, such as type of surgery (intraabdominal distension) or anaesthetic agents (volatile), were responsible for provoking nausea and vomiting. Alternatively, our sample size was derived from a power calculation intended to detect a reduction in morphine use, not a reduction in sideeffects. Thus a much larger study might have detected such a difference. In any case, the use of NSAIDs to reduce opioid consumption, and hence the risk of opioid-induced side-effects, is widely accepted 1,2 . The incidence of side-effects caused by NSAIDs in the postoperative period is likely to be low especially if patients with known contraindications to these drugs are excluded from receiving them 1 . No patient suffered from such side-effects in this study.
We used 40 mg tenoxicam, a higher dose than had been used previously 4 , without any untoward effects. Thus, we suggest that this is a sufficient loading dose of tenoxicam for patients requiring a short period of parenteral analgesia. However, the beneficial effect of tenoxicam appears to be of a more limited duration than might be expected from its long half-life. It has been determined that following intravenous administration, the plasma levels of tenoxicam decline rapidly during the first two hours mainly due to redistribution processes 7 . It may be that plasma concentration fell below therapeutic levels after six hours. Therefore, we suggest that it may be of benefit to divide the 40 mg into two doses, giving the second 20 mg at 12 hours postoperatively, or continue the drug as its oral preparation in order to prolong the analgesic effect.
From these results, we suggest that further study of tenoxicam is warranted to determine its analgesic effect in other forms of surgery, perhaps also continuing the drug as its oral preparation longer into the postoperative period.
